Infliximab use in ulcerative colitis flare with clostridium difficile infection: A report of two cases and literature review
| Autor: | Bhupinder Romana, Abdulmajeed Albarrak, Mohamad H. Yousef, Veysel Tahan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Ulcerative Colitis Flare medicine.medical_specialty genetic structures dual medicine.drug_class Antibiotics lcsh:Medicine Case Report tumor necrosis Inflammatory bowel disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine medicine ulcerative colitis lcsh:R5-920 comorbidity infliximab treatment business.industry Incidence (epidemiology) lcsh:R Clostridium difficile clostridium difficile medicine.disease Ulcerative colitis Infliximab digestive system diseases 030104 developmental biology 030211 gastroenterology & hepatology business lcsh:Medicine (General) General Economics Econometrics and Finance Dysbiosis medicine.drug |
| Zdroj: | İstanbul Kuzey Klinikleri, Vol 5, Iss 3, Pp 256-260 (2018) Northern Clinics of Istanbul |
| ISSN: | 2148-4902 |
| Popis: | Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in patients with inflammatory bowel disease (IBD), especially in ulcerative colitis (UC). The incidence and severity of CDI in IBD has shown an increasing trend in the last two decades. Patients with IBD are predisposed to CDI secondary to the recurrent use of antibiotics, corticosteroids, and immunosuppressants and secondary to dysbiosis. It is clinically challenging to distinguish the symptoms of CDI from an IBD flare. The worsening of IBD symptoms demands escalation of steroids or initiation of biologics. However, the management of CDI in IBD, not responding to antibiotics, is not well described beyond a few case reports. We report two cases of CDI with active UC flare. The patients did not respond to antibiotics or intravenous corticosteroids but had rapid resolution of CDI symptoms after receiving infliximab infusion. The optimal dosing and infusion frequency of infliximab in management of CDI in UC/IBD remains to be established. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|